Manejo paliativo de la disnea en el paciente terminal


  • Gabriel Carvajal Valdy Centro Nacional del Control del Dolor y Cuidados Paliativos
  • Marco Ferrandino Carballo Centro Nacional del Control del Dolor y Cuidados Paliativos
  • Isaías Salas-Herrera Centro Nacional del Control del Dolor y Cuidados Paliativos


Palabras clave:

disnea, cuidados paliativos, opiodes


El manejo adecuado de síntomas en pacientes terminales permite a los pacientes y a sus seres queridos el espacio para resolver asuntos emocionales, psicológicos y espirituales. La disnea es un problema frecuente para los pacientes con condiciones terminales, y con estrategias clínicas efectivas puede aliviarse el síntoma, en la mayoría de los casos. El manejo sintomático puede llevarse a cabo concomitantemente con la corrección de la causa de fondo cuando esté justifi cada, y aunque los opioides son la terapia farmacológica de primera línea, el oxígeno suplementario y las benzodiacepinas pueden ser coadyuvantes cuando se encuentren indicados. En los casos refractarios a tratamiento, la sedación puede ser apropiada. Se realiza una revisión sobre el manejo óptimo de la disnea en pacientes con condiciones terminales, con base en la evidencia reciente más relevante.


American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159:321–40.

Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage 2001;2:95–102.

Hayes AW, Philip J, Spruyt OW. Patient reporting and doctor recognition of dyspnoea in a comprehensive cancer centre. Intern Med J 2006;36:381-384.

Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest. 1986;89:234-236.

Bruera E, Schmitz B, Pither J, Neumann C, Hanson J. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 2000;19:357-362.

Higginson I, McCarthy M. Measuring symptoms in terminal cancer:

are pain and dyspnoea controlled? J R Soc Med 1989;82:264–267.

Mercadante S, Casuuccio A, Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage 2000;20:104–112.

Chang VT, Hwang SS, Feuerman M, Kasimis BS. Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center. Cancer 2000;88:1175-1183.

Lynn J. Perspectives on care at the close of life. Serving patients who may die soon and their families: the role of hospice and other services. JAMA 2001;285:925-932.

Thomas JR, von Gunten F. Management of Dyspnea. J Support Oncol.


Barrett KE, Barman SM, Boitano S, Brooks H. Regulation of Respiration. En: Barrett KE, Barman SM, Boitano S, Brooks H. Ganong’s Review of Medical Physiology. San Francisco: McGrawHill; 2005.657-660.

Weir E, López-Barneo J, Buckler K, Archer S. Acute Oxygen-Sensing Mechanisms. NEJM. 2005;353:2042-2055.

Parkes M. Breath-holding and its breakpoint. Exp Physiol 2006;91:115.

Richerson GB, Boron WF. Control of ventilation. En: Boron WF. Medical Physiology. A Cellular and Molecular Approach. Philadelphia: Saunders; 2009 712-720.

Eccles R. Role of cold receptors and menthol in thirst, the drive to breathe and arousal. Appetite 2000; 34:29-35.

Nishino T, Tagaito Y, Sakurai Y. Nasal inhalation of l-menthol reduces respiratory discomfort associated with loaded breathing. Am J Respir Crit Care Med 1997;156:309-313.

Sant’Ambrogio F, Anderson J, Sant’Ambrogio G. Effect of l- menthol on laryngeal receptors. J Appl Physiol. 1991;70:788-793.

Colebatch JG, Adams L, Murphy K, Martin AJ, Lammertsma AA, Tochon- Danguy HJ y colaboradores. Regional cerebral blood fl ow during volitional breathing in man. J Physiol 1991;443:91–103.

Corfi eld DR, Murphy K, Guz A. Does the motor cortical control of the diaphragm “bypass” the brain stem respiratory centres in man? Respir Physiol 1998;114:109-117.

Feldman JL, Del Negro CA. Looking for inspiration: new perspectives on respiratory rhythm. Nat Rev Neurosci 2006;7:232-242.

von Leupoldt A, Dahme B. Cortical substrates for the perception of dyspnea. Chest. 2005;128:345-354.

McKay LC, Evans KC, Frackowiak RS, Corfi eld DR. Neural correlates of voluntary breathing in humans. J Appl Physio 2003;95:1170-1178.

Brown S, Ngan E, Liotti M. A larynx area in the human motor cortex. Cereb Cortex. 2008;18:837-845.

Banzett RB, Mulnier HE, Murphy K, Rosen SD, Wise RJ, Adams L. Breathlessness in humans activates insular cortex. Neuroreport 2000;11:2117–2120.

Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RS, Corfi eld DR. BOLD fMRI identifi es limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 2002;88:1500 –1511.

Frackowiak RS, Corfi eld DR. A bilateral cortico-bulbar network associated with breath holding in humans, determined by functional magnetic resonance imaging. Neuroimage 2008;40:1824-1832.

Gilman SA, Banzett RB. Physiologic changes and clinical correlates of advanced dyspnea. Curr Opin Support Palliat Care 2009;3:93-97.

Heyse-Moore L, Beynon T, Ross V. Does spirometry predict dyspnoea in advanced cancer? Palliat Med 2000;14:189-195.

Laugsand E, Sprangers M, Bjordal K, Skorpen F, Kaasa S, Klepstad P. Health care providers underestimate symptom intensities of cancer patients:A multicenter European study. Health Qual Life Outcomes 2010;8:104-117.

Campbell M, Templin T, Walch J. Patients Who Are Near Death Are Frequently Unable To Self-Report Dyspnea. Journal of palliative medicine 2009; 12: 881-884.

Campbel M. Assessing respiratory distress when the patient cannot report dyspnea. Nurs Clin North Am 2010;45: 363-373.

Campbell ML, Templin T, Walch J. Dyspnea, A Respiratory Distress Observation Scale for Patients Unable To Self-Report. J Palliat Med 2010;13: 285-90.

Gift A. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehab Nurs 1989;14:323–325.

Borg G. Perceived Exertion as an indicator of somatic stress. Scandinavian journal of Rehabilitation Medicine 1970;2: 92-98.

Mador MJ, Kufel TJ. Reproducibility of visual analogue scale measurements of dyspnea in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:82-87.

Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9.

Reddy SK, Parsons HA, Elsayem A, Palmer JL, Bruera E. Characteristics and Correlates of Dyspnea in Patients with Advanced Cancer. J Palliat Med 2009;12: 29-36.

Fohr S. The double effect of pain medication: separating myth from reality. J Palliat Med 1998;1: 315-28.

Strasser F, Blum D, Bueche D. Invasive palliative interventions: when are they worth it and when are they not? Cancer J 2010;16:483-487.

Stuart B. Palliative care and hospice in advanced heart failure. J Palliat Med 2007;10(1):210-228.

Johnson MJ, Oxberry SG. The management of dyspnoea in chronic heart failure. Curr Opin Support Palliat Care 2010;4:63-78.

Russon L, Mooney A. Palliative and end-of-life care in advanced renal failure. Clin Med 2010;10:279–281.

Fisher J. Palliating symptoms other than pain. Aust Fam Physician 2006;35:766-770.

Rocker GM, Sinuff T, Horton R, Hernandez P. Advanced chronic obstructive pulmonary disease: innovative approaches to palliation. J Palliat Med 2007;10:783-797.

Luce JM, Luce JA. Perspectives on care at the close of life. Management of dyspnea in patients with far-advanced lung disease: “once I lose it, it’s kind of hard to catch it.”. JAMA 2001;285:13311337.

Yohannes A. Palliative care provision for patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2007;5:1723.

Rocker G, Horton R, Currow D, Goodridge D, Young J, Booth S. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax 2009;64:910-915.

Robinson, W. Palliative care in cystic fi brosis. J Palliat Med. 2000;3:187-192.

Robinson, W. Palliative and end-of-life care in cystic fi brosis: what we know and what we need to know. Curr Opin Pulm Med 2009;15:621– 625.

Tripodoro VA, De Vito EL. Management of dyspnea in advanced motor neuron diseases. Curr Opin Support Palliat Care 2008;2:173179.

Kvale PA, Selecky PA, Prakash UB; American College of Chest Physicians. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:368S403S.

Koh NY, Koo WH. Polypharmacy in Palliative Care: can it be reduced ? Singapore Med J 2002;43:279-283.

Goh, CR. Minimising Polypharmacy –a Challenge in Palliative Care. Singapore Med J 2002;43: 273-276.

Garfi nkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J 2007;9:430-434.

Bausewein C, Booth S, Gysels M, Higginson I. Nonpharmacological interventions for breathlessness in advanced stages of malignant and nonmalignant diseases. Cochrane Database Syst Rev 2008.

Buckholz GT, von Gunten CF. Nonpharmacological management of dyspnea. Current Opinion in Supportive and Palliative Care. 2009;3:98–102.

Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006.

Pomidori L, Campigotto F, Amatya TM, Bernardi L, Cogo A. Effi cacy and tolerability of yoga breathing in patients with chronic obstructive pulmonary disease: a pilot study. J Cardiopulm Rehabil Prev 2009;29:133-137.

Vadiraja SH, Rao MR, Nagendra RH, Nagarathna R, Rekha M, Vanitha N, Gopinath SK, Srinath B, Vishweshwara M, Madhavi Y, S Ajaikumar B, Ramesh SB, Rao N. Effects of yoga on symptom management in breast cancer patients: A randomized controlled trial. Int J Yoga 2009;2:73-79.

Donesky-Cuenco D, Nguyen H, Paul S, Carrieri-Kohlman V. Yoga Therapy Decreases Dyspnea-Related Distress and Improves Functional Performance in People with Chronic Obstructive Pulmonary Disease: A Pilot Study. The journal of alternative and complementary medicine 2009;15:225–234.

Galbraith S, Fagan P, Perkins P, Lynch A, Booth S. Does the Use of a Handheld Fan Improve Chronic Dyspnea? A Randomized, Controlled, Crossover Trial. J Pain Symptom Manage 2010;39:831-838.

Crisafulli E, Costi S, De Blasio F, Biscione G, Americi F, Penza S, Eutropio E, Pasqua F, Fabbri LM, Clini EM. Effects of a walking aid in COPD patients receiving oxygen therapy. Chest 2007;131:1068– 1074.

Bloch-Salisbury E, Binks AP, Banzett RB, Schwartzstein RM. Mechanical chest-wall vibration does not relieve air hunger. Respir Physiol Neurobiol 2003;134:177–190.

Clary PL, Lawson P. Pharmacologic pearls for end-of-life care. Am fam Phys 2009;79:1059-1065.

Elsayem A, Bruera E. High-dose corticosteroids for the management of dyspnea in patients with tumor obstruction of the upper airway. Support Care Cancer 2007;15:1437-1439.

Kallas de Carvalho F, Filho JT, Vianna EO, Silva GA, Martinez JA. Do steroids interfere in dyspnoea sensation? Respir Med 2002;96(7):511-524.

Bruce DM, Heys SD, Eremin O. Lymphangitis carcinomatosa: a literature review. J R Coll Surg Edinb. 1996;41:7-13.

Wan JF, Bezjak A. Superior vena cava syndrome. Emerg Med Clin North Am 2009;27(2):243-255.

Cranston JM, Crockett A, Moss J, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005.

Moore RP, Berlowitz DJ, Denehy L, Pretto JJ, Brazzale DJ, Sharpe K y colaboradores. A randomised trial of domiciliary, ambulatory oxygen in patients with COPD and dyspnoea but without resting hypoxaemia. Thorax 2010.

Thakur N, Blanc P, Julian L, Yelin E, Katz P, Sidney S y colaboradores. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis 2010;6: 263–269.

Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE, Marcello J y colaboradores. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010;376(9743):784793.

Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008;11:1133-1153.

Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:939-944.

Kallet R. The Role of Inhaled Opioids and Furosemide for the Treatment of Dispnoea. Respir Care 2007;52:900-910.

Benitez-Rosario MA, Feria M. Oral transmucosal fentanyl citrate in the management of dyspnea crises in cancer patients. Journal of Palliative and Symptom Management 2005;30:395-397.

Pattinson K. Opioids and the control of respiration. Br J Anaesth 2008;100:747–758.

Baumgärtner U, Buchholz HG, Bellosevich A, Magerl W, Siessmeier T, Rolke R y colaboradores. High opiate receptor binding potential in the human lateral pain system. Neuroimage 2006;30:692– 699.

Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron 2007;55:377–391.

Pattinson K, Governo R, MacIntosh B, Russell E , Corfi eld D, Tracey I y colaboradores. Opioids Depress Cortical Centers Responsible for the Volitional Control of Respiration. The Journal of Neuroscience 2009;29:8177– 8186.

Bailey PL, Lu JK, Pace NL, Orr JA, White JL, Hamber EA y colaboradores. Effects of intrathecal morphine on the ventilatory response to hypoxia. N Engl J Med 2000;342:1228 –1234.

Clemens KE, Quednau I, Klaschik E. Is There a Higher Risk of Respiratory Depression in Opioid-Naïve Palliative Care Patients during Symptomatic Therapy of Dyspnea with Strong Opioids? J Palliat Med 2008;11:204-216.

Hallenbeck J, Gauna A, Kang S, Triano M, Swatko ER, Vanston VJ. Oral Transmucosal Fentanyl Citrate for Dyspnea in Terminally Ill Patients: An Observational Case Series. Journal of Palliative Medicine 2008;11:643-648.

Sitte T, Bausewein C. Intranasal fentanyl for episodic breathlessness. Pain Symptom Manage 2008;36:3-6

Macdonald N, Macleod SM. Has the time come to phase out codeine? CMAJ. 2010

Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P y colaboradores. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-2831.

Rocker G, Horton R, Currow D, Goodridge D, Young J, Booth S. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax 2009;64:910-915.

Lang E, Jedeikin R. Acute respiratory depression as a complication of nebulised morphine. Can J Anaesth 1998;45:60-62.

Krajnik M, Podolec Z, Siekierka M, Sykutera M, Pufal E, Sobanski P y colaboradores. Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage 2009;38:747-757.

Chochinov HMC. Psychiatry and the terminally ill. Canadian Journal of Psychiatry 2000;45:143-150.

Periyakoil VS, Skultety K, Sheikh J. Panic, Anxiety, and Chronic Dyspnea. J Palliat Med 2005;8:453-459.

Jackson KC, Lipman AG. Drug therapy for anxiety in adult palliative care patients. Cochrane Database Syst Rev 2004

Stiel S, Krumm N, Schroers O, Radbruch L, Elsner F. Indications and use of benzodiazepines in a palliative care unit. Schmerz 2008;22:665671.

Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C.

Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010

Navigante A, Castro MA, Cerchietti LC. Morphine Versus Midazolam as Upfront Therapy to Control Dyspnea Perception in Cancer Patients While Its Underlying Cause Is Sought or Treated. J Pain Symptom Manage 2010;39(5):820-830.

Currow DC, Abernethy AP. Potential Opioid Sparing Effect of Regular Benzodiazepines in Dyspnea: Longer Duration of Studies Needed. J Pain Symptom Manage 2010.

Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982;71: 248-252.

Kraus JW, Desmond PV, Marshall JP, Johnson RF,Schenker S, Wilkinson GR. Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 1978;24:411–419.

Rhee C, Broadbent AM. Palliation and liver failure: palliative medications dosage guidelines. J Palliat Med 2007: 10; 677-685.

Tyler L. Dyspnea in Palliative Care Patients. Journal of Pharmaceutical Care in Pain & Symptom Control 2000;7:109-127.

Pecking M, Montestruc F, Marquet P, Wodey E, Homery MC, Dostert P. Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. Br J Clin Pharmacol 2002;54:357362.




Cómo citar

Carvajal Valdy, G., Ferrandino Carballo, M., & Salas-Herrera, I. (2011). Manejo paliativo de la disnea en el paciente terminal. Acta Médica Costarricense , 53(2), 79-87.